| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion due to NICE appraisal TA116: Gemcitabine for the treatment of metastatic breast cancer |
|
Medicine details |
|
| Medicine name | gemcitabine (Gemzar®) |
| Formulation | powder for solution for infusion |
| Reference number | 156 |
| Indication | Treatment of patients with metastatic breast cancer, in combination with paclitaxel, who have relapsed following adjuvant/neoadjuvant chemotherapy. Prior chemotherapy should have included an anthracycline, unless contra-indicated |
| Company | Eli Lilly & Co Ltd |
| BNF chapter | Malignant disease & immunosuppression |
| Assessment type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 24/01/2007 |
| NICE guidance | TA116: Gemcitabine for the treatment of metastatic breast cancer |